salVageNCT06114108
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Start date: Dec 21, 2023 to Feb 19, 2024 Show 6 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 13 words
- Interventions modified
- Secondary endpoints: 5 to 17
- Study description expanded, about 14 words
- Study title expanded, about 2 words
- Notable Eligibility criteria expanded, about 24 words
- Study completion date: Nov 1, 2027 to Mar 1, 2028
- Minor Study sites: 8 to 7v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 1, 2024 to Dec 21, 2023
- Site details revised at 8 of 8 sites
- Notable Start date: Nov 1, 2023 to Feb 1, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (17)
Show 12 moreShow less
Arms and interventions
All patients receive standard first-line systemic therapy according to the molecular analysis of the diagnostic biopsy, per the standard of the treating center. After randomization, patients additionally undergo LAT of the primary tumor and all measurable residual metastases (except PET-negative bone metastases): complete surgical resection of the primary tumor with mediastinal lymph node sampling and/or radical radiotherapy (preferably stereotactic body radiotherapy, SBRT), and surgery and/or SBRT of the metastases. The first LAT is performed within 1 to 35 days after randomization. Choice and sequence of LAT (primary tumor versus metastases) are decided by the local multidisciplinary tumor board (MDT) after interdisciplinary counseling of the patient. Systemic anticancer therapy then continues as standard of care: chemotherapy, chemo-immunotherapy or immunotherapy restarts at the earliest 14 days after LAT; targeted therapy continues throughout.
Patients receive systemic anticancer therapy alone (chemotherapy, chemo-immunotherapy, immunotherapy alone, or targeted therapy), per the standard of the treating center. Local ablative treatment is not allowed. Assigned interventions: Other: Systemic anticancer therapy
Other: Systemic anticancer therapy, Surgery
Radiation: Radiotherapy
Sites
7 sites in 1 country